Recombinant prion protein refolded with lipid and RNA has the biochemical hallmarks of a prion but lacks in vivo infectivity.
During prion infection, the normal, protease-sensitive conformation of prion protein (PrP(C)) is converted via seeded polymerization to an abnormal, infectious conformation with greatly increased protease-resistance (PrP(Sc)). In vitro, protein misfolding cyclic amplification (PMCA) uses PrP(Sc) in prion-infected brain homogenates as an initiating seed to convert PrP(C) and trigger the self-propagation of PrP(Sc) over many cycles of amplification. While PMCA reactions produce high levels of protease-resistant PrP, the infectious titer is often lower than that of brain-derived PrP(Sc). More recently, PMCA techniques using bacterially derived recombinant PrP (rPrP) in the presence of lipid and RNA but in the absence of any starting PrP(Sc) seed have been used to generate infectious prions that cause disease in wild-type mice with relatively short incubation times. These data suggest that lipid and/or RNA act as cofactors to facilitate the de novo formation of high levels of prion infectivity. Using rPrP purified by two different techniques, we generated a self-propagating protease-resistant rPrP molecule that, regardless of the amount of RNA and lipid used, had a molecular mass, protease resistance and insolubility similar to that of PrP(Sc). However, we were unable to detect prion infectivity in any of our reactions using either cell-culture or animal bioassays. These results demonstrate that the ability to self-propagate into a protease-resistant insoluble conformer is not unique to infectious PrP molecules. They suggest that the presence of RNA and lipid cofactors may facilitate the spontaneous refolding of PrP into an infectious form while also allowing the de novo formation of self-propagating, but non-infectious, rPrP-res.
Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Disease, National Institutes of Health, Hamilton, Montana, USA.
Andrew G
AG
Timmes
Roger A
RA
Moore
Elizabeth R
ER
Fischer
Suzette A
SA
Priola
D000818:Animals; D001921:Brain / Q000378:metabolism / Q000473:pathology; D002460:Cell Line; D003902:Detergents / Q000737:chemistry; D005260:Female; D008055:Lipids / Q000737:chemistry*; D051379:Mice; D018621:PrPC Proteins / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure; D018620:PrPSc Proteins / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure; D011328:Prions / Q000737:chemistry* / Q000378:metabolism / Q000648:ultrastructure; D058849:Protein Refolding; D059748:Proteolysis; D012313:RNA / Q000737:chemistry*; D011994:Recombinant Proteins / Q000737:chemistry* / Q000378:metabolism / Q000648:ultrastructure; D012995:Solubility
D003902:Detergents; D008055:Lipids; D018621:PrPC Proteins; D018620:PrPSc Proteins; D011328:Prions; D011994:Recombinant Proteins; D012313:RNA